Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Clinical Phase
PHASE2
Total Enrollment
20 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-02-12
Study Completion Date
2026-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this study, common variable immunodeficiency (CVID) patients will all receive the study drug, leniolisib, for a treatment period of 6 months. Participants will start on a lower dose of leniolisib, followed by a mid and then a higher dose level. The primary goal is to assess the safety and tolerability of leniolisib, and secondary goal is to assess the potential for leniolisib to provide benefits for patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy
NCT02028403
HIV Infections
COMPLETED
PHASE1
Study of Anti-HIV Therapy Intensification
NCT00034086
HIV Infections
COMPLETED
NA
Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients
NCT02390297
HIV-1 Infection
Receipt of Cal-1 Modified Hematopoietic Cellular Products
ACTIVE_NOT_RECRUITING
Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART).
NCT02054286
HIV Infection
COMPLETED
PHASE1/PHASE2
Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART
NCT03787095
HIV Infections
TERMINATED
PHASE1/PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study includes administration of increasing dose levels of leniolisib in approximately 20 CVID patients presenting with clinical manifestations of immune dysregulation at study entry. Enrollment will include both patients without and those with genetic drivers identified for their CVID.
All subjects participating will receive leniolisib film-coated tablets (FCTs) with a planned dose regimen consisting of a starting dose of 10 mg twice daily (BID) for 4 weeks, followed by a dose escalation to 30 mg BID for 4 weeks, and then 70 mg BID for an additional 16 weeks. Dose adjustments are allowed during treatment if deemed clinically necessary.
Subjects not continuing leniolisib treatment outside the current protocol will be followed up, with the EoS visit planned to occur approximately 28 days after last dose of leniolisib.
All subjects participating will receive leniolisib film-coated tablets (FCTs) with a planned dose regimen consisting of a starting dose of 10 mg twice daily (BID) for 4 weeks, followed by a dose escalation to 30 mg BID for 4 weeks, and then 70 mg BID for an additional 16 weeks. Dose adjustments are allowed during treatment if deemed clinically necessary.
Subjects not continuing leniolisib treatment outside the current protocol will be followed up, with the EoS visit planned to occur approximately 28 days after last dose of leniolisib.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Common Variable Immunodeficiency (CVID)
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Leniolisib
All subjects participating will receive leniolisib film-coated tablets (FCTs) with a planned dose regimen consisting of a starting dose of 10 mg twice daily (BID) for 4 weeks, followed by a dose escalation to 30 mg BID for 4 weeks, and then 70 mg BID for an additional 16 weeks.
Group Type
EXPERIMENTAL
Leniolisib
Intervention Type
DRUG
Planned dose will range from 10 mg twice daily to 70 mg twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Leniolisib
Planned dose will range from 10 mg twice daily to 70 mg twice daily
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Joenja
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Subject is 12 to 75 years of age (inclusive).
a. Specifically at sites located in the United Kingdom subjects must be 18 to 75 years of age (inclusive)
2. Subject must have a minimum body weight of 45 kg
3. Subject has a clinical diagnosis of CVID supported by all of the following (a thru c):
1. A low IgG level compared to age-adjusted reference range \[OR if this cannot be documented, subject must have one of the following: i) absent isohemagglutinins and/or poor response to vaccines; or ii) Low class-switched memory B cells less than 2%\]
2. Low IgA and/or IgM compared to age-adjusted reference range
3. No identified secondary causes of hypogammaglobulinemia
4. Inborn Errors of Immunity/ PID Panel testing:
1. Lacks an identified pathogenic/likely pathogenic genetic driver for their CVID primary immunodeficiency OR
2. Subject has an identified pathogenic/likely pathogenic genetic driver(s) for their CVID limited to the following genes: TNFRSF13B (TACI), TNFRSF13C (BAFFR), CD19, CD20, CD81, CR2 (CD21), LRBA, CTLA4, NFKB1, NFKB2, IKZF1 (excluding variants associated with combined immune deficiency), CARD11 (gain of function), SH3KBP1, SEC61A1 IRF2BP2, CTNNBL1, TWEAK or PTEN.
5. Subject has lymphoproliferation, as evidenced by CT imaging: splenomegaly with craniocaudal spleen measurement \>10 cm and/or lymphadenopathy with at least 1 measurable index lymph node (long axis \>1.5 cm) as per Cheson methodology.
6. Subject has at least ONE of the following CVID clinical manifestations of immune dysregulation:
1. Clinical symptoms related to splenomegaly or lymphadenopathy which interfere with activities of daily living or are associated with chronic pain, dyspnea, functional impairment, or limitations in usual activities
2. One or more blood cytopenias related to CVID (and not due to other medical conditions such as iron-deficiency or lead exposure) defined as hemoglobin \<10 g/dL, platelet count \<100,000/µL, and/or neutrophil count \<1,000/µL
3. Previous pathologic confirmation of ILD and attributed to CVID by the Investigator with quantifiable CT chest imaging findings evident on baseline CT scan
4. Clinical diagnosis of CVID enteropathy or other GI tract diagnosis attributable to CVID by the Investigator which involves the small intestine and meets the following enteropathy criteria:
i. Clinical symptoms of GI disease including at least 1 of: abdominal pain or diarrhea at least 3 days of the week for at least 4 weeks or longer, or dependence on supplemental enteral or parenteral nutrition ii. Lacks a clinical diagnosis of Celiac Disease, and negative human leukocyte antigen (HLA)-DQ2 and -DQ8 testing at screening iii. Presence of small bowel villous shortening/atrophy/blunting with or without intraepithelial lymphocytosis noted in a pathology report pertaining to a small bowel biopsy performed within 5 years of enrollment iv. Negative stool PCR Gastrointestinal Profile at screening
7. At screening, vital signs. Ranges:
Systolic blood pressure 80-159 mm Hg Diastolic blood pressure 50-109 mm Hg Pulse rate 50-110 beats per minute (bpm) Oxygen saturation 93-100%
8. Subjects or their legal representatives (for subjects under the age of 18 years) must be able to communicate with the Investigator and understand and comply with the requirements of the study, including an ability to provide written informed consent.
a. Specifically at sites located in the United Kingdom subjects must be 18 to 75 years of age (inclusive)
2. Subject must have a minimum body weight of 45 kg
3. Subject has a clinical diagnosis of CVID supported by all of the following (a thru c):
1. A low IgG level compared to age-adjusted reference range \[OR if this cannot be documented, subject must have one of the following: i) absent isohemagglutinins and/or poor response to vaccines; or ii) Low class-switched memory B cells less than 2%\]
2. Low IgA and/or IgM compared to age-adjusted reference range
3. No identified secondary causes of hypogammaglobulinemia
4. Inborn Errors of Immunity/ PID Panel testing:
1. Lacks an identified pathogenic/likely pathogenic genetic driver for their CVID primary immunodeficiency OR
2. Subject has an identified pathogenic/likely pathogenic genetic driver(s) for their CVID limited to the following genes: TNFRSF13B (TACI), TNFRSF13C (BAFFR), CD19, CD20, CD81, CR2 (CD21), LRBA, CTLA4, NFKB1, NFKB2, IKZF1 (excluding variants associated with combined immune deficiency), CARD11 (gain of function), SH3KBP1, SEC61A1 IRF2BP2, CTNNBL1, TWEAK or PTEN.
5. Subject has lymphoproliferation, as evidenced by CT imaging: splenomegaly with craniocaudal spleen measurement \>10 cm and/or lymphadenopathy with at least 1 measurable index lymph node (long axis \>1.5 cm) as per Cheson methodology.
6. Subject has at least ONE of the following CVID clinical manifestations of immune dysregulation:
1. Clinical symptoms related to splenomegaly or lymphadenopathy which interfere with activities of daily living or are associated with chronic pain, dyspnea, functional impairment, or limitations in usual activities
2. One or more blood cytopenias related to CVID (and not due to other medical conditions such as iron-deficiency or lead exposure) defined as hemoglobin \<10 g/dL, platelet count \<100,000/µL, and/or neutrophil count \<1,000/µL
3. Previous pathologic confirmation of ILD and attributed to CVID by the Investigator with quantifiable CT chest imaging findings evident on baseline CT scan
4. Clinical diagnosis of CVID enteropathy or other GI tract diagnosis attributable to CVID by the Investigator which involves the small intestine and meets the following enteropathy criteria:
i. Clinical symptoms of GI disease including at least 1 of: abdominal pain or diarrhea at least 3 days of the week for at least 4 weeks or longer, or dependence on supplemental enteral or parenteral nutrition ii. Lacks a clinical diagnosis of Celiac Disease, and negative human leukocyte antigen (HLA)-DQ2 and -DQ8 testing at screening iii. Presence of small bowel villous shortening/atrophy/blunting with or without intraepithelial lymphocytosis noted in a pathology report pertaining to a small bowel biopsy performed within 5 years of enrollment iv. Negative stool PCR Gastrointestinal Profile at screening
7. At screening, vital signs. Ranges:
Systolic blood pressure 80-159 mm Hg Diastolic blood pressure 50-109 mm Hg Pulse rate 50-110 beats per minute (bpm) Oxygen saturation 93-100%
8. Subjects or their legal representatives (for subjects under the age of 18 years) must be able to communicate with the Investigator and understand and comply with the requirements of the study, including an ability to provide written informed consent.
Exclusion Criteria
1. Laboratory evidence of significant T cell deficiency including CD4+ T cells \<200/uL.
2. Laboratory evidence of significant NK cell deficiency including NK cells \<1% of peripheral blood lymphocytes or less than 50/mcL.
3. Clinical history of infections suggestive of clinically significant T cell or NK cell deficiency such as Pneumocystis jirovecii, atypical mycobacteria, severe warts, or unusually severe (as determined by the PI) infections with herpesviruses.
4. Presence of uncontrolled chronic/recurrent infectious disease (except those considered to be characteristic of antibody deficiency).
5. Positive blood polymerase chain reaction (PCR) for cytomegalovirus.
6. Evidence of tuberculosis infection
7. Positive blood cryptococcal antigen
8. Previous or concurrent use of immunosuppressive medication, such as:
* Use of an mTOR inhibitor or a PI3K inhibitor within 3 weeks.
* Rituximab or other B cell depleting antibodies, belimumab, cyclophosphamide, or alemtuzumab within 6 months.
* Cyclosporine A, mycophenolate mofetil, 6-mercaptopurine, azathioprine, methotrexate, tacrolimus, ruxolitinib, or other Janus kinase (JAK) inhibitors within 3 weeks.
* Glucocorticoids above 25 mg prednisone or equivalent per day within 2 weeks
* Immunosuppressive monoclonal or polyclonal antibody therapeutics such as directed against TNF-alpha, α₄β₇ integrin, IL-6, IL-12/IL-23 and others within 5 half-lives
* Other immunosuppressive agents expected to have a significant impact on immune cell number or function.
* Abatacept is allowed during study if the subject has been receiving a stable dosing regimen for more than 3 months .
* Enteral budesonide is allowed during study if the subject has been receiving a stable dosing regimen for more than 3 months.
9. Subject is receiving concurrent treatment with another investigational therapy or use of another investigational therapy less than 4 weeks or 5 half-lives (whichever is longer).
10. HIstory of hypersensitivity to the study drug or to drugs of similar chemical classes.
11. Current use of medication known to be a strong inhibitor, or moderate or strong inducer, of isoenzyme cytochrome P450 CYP3A.
12. Current use of medications that, to a larger extent, are BCRP, OATP1B1, and/or OATP1B3 substrates.
13. History of HIV or positive test result at screening.
14. Any surgical or medical condition which may jeopardize the subject in case of participation in the study.
* Chronic need for supplemental oxygen or invasive or non-invasive respiratory support.
* Liver failure or clinically significant liver disease or dysfunction as indicated by alanine transaminase (ALT) or aspartate transaminase (AST) greater than 2.5 times the upper limit of normal, bilirubin greater than 1.5 times the upper limit of normal, international normalized ratio (INR) greater than 1.5 in the absence of anticoagulation, or presence of diuretic refractory ascites.
* Elevation of ALT or AST up to 6 times the upper limit of normal is allowed if elevation is determined to be a consequence of immune dysregulation by the site Principal Investigator and if the elevation has been stable for 3 months prior to enrollment.
* History of significant renal injury/renal disease severely affecting renal function or presence of impaired renal function as indicated by estimated glomerular filtration rate of less than 30 mL/min/1.73 m2.
15. A positive hepatitis B surface antigen (HBsAg), positive hepatitis B PCR, positive hepatitis C PCR, or positive hepatitis C antibody result at screening.
16. Administration of live vaccines starting from 6 weeks before first dose of study medication
17. Subject has a history of malignancy (except lymphoma) within 3 years before the first dose of study medication or has evidence of residual disease from a previously diagnosed malignancy, except for adequately treated cancers of the skin (basal or squamous cell) or carcinoma in situ of the uterine cervix.
18. Subject has a previous diagnosis of lymphoma that has been treated with chemotherapy, radiotherapy, or transplant within 1 year of the first dose of study medication or is anticipated to require lymphoma treatment within 6 months of the first dose of study medication.
19. Subject has uncontrolled post-transplant lymphoproliferative disease-like Epstein-Barr virus related lymphoproliferative disease.
20. Donation or loss of 400mL or more of blood within 8 weeks before the first dose of study medication
21. Subject has had major surgery requiring hospitalization or radiotherapy within 4 weeks prior to the first dose of study medication or has a planned or expected major surgical procedure during the study period.
22. Pregnant or nursing (lactating) women.
23. Individuals of child-bearing potential, unless they are using highly effective methods of contraception
2. Laboratory evidence of significant NK cell deficiency including NK cells \<1% of peripheral blood lymphocytes or less than 50/mcL.
3. Clinical history of infections suggestive of clinically significant T cell or NK cell deficiency such as Pneumocystis jirovecii, atypical mycobacteria, severe warts, or unusually severe (as determined by the PI) infections with herpesviruses.
4. Presence of uncontrolled chronic/recurrent infectious disease (except those considered to be characteristic of antibody deficiency).
5. Positive blood polymerase chain reaction (PCR) for cytomegalovirus.
6. Evidence of tuberculosis infection
7. Positive blood cryptococcal antigen
8. Previous or concurrent use of immunosuppressive medication, such as:
* Use of an mTOR inhibitor or a PI3K inhibitor within 3 weeks.
* Rituximab or other B cell depleting antibodies, belimumab, cyclophosphamide, or alemtuzumab within 6 months.
* Cyclosporine A, mycophenolate mofetil, 6-mercaptopurine, azathioprine, methotrexate, tacrolimus, ruxolitinib, or other Janus kinase (JAK) inhibitors within 3 weeks.
* Glucocorticoids above 25 mg prednisone or equivalent per day within 2 weeks
* Immunosuppressive monoclonal or polyclonal antibody therapeutics such as directed against TNF-alpha, α₄β₇ integrin, IL-6, IL-12/IL-23 and others within 5 half-lives
* Other immunosuppressive agents expected to have a significant impact on immune cell number or function.
* Abatacept is allowed during study if the subject has been receiving a stable dosing regimen for more than 3 months .
* Enteral budesonide is allowed during study if the subject has been receiving a stable dosing regimen for more than 3 months.
9. Subject is receiving concurrent treatment with another investigational therapy or use of another investigational therapy less than 4 weeks or 5 half-lives (whichever is longer).
10. HIstory of hypersensitivity to the study drug or to drugs of similar chemical classes.
11. Current use of medication known to be a strong inhibitor, or moderate or strong inducer, of isoenzyme cytochrome P450 CYP3A.
12. Current use of medications that, to a larger extent, are BCRP, OATP1B1, and/or OATP1B3 substrates.
13. History of HIV or positive test result at screening.
14. Any surgical or medical condition which may jeopardize the subject in case of participation in the study.
* Chronic need for supplemental oxygen or invasive or non-invasive respiratory support.
* Liver failure or clinically significant liver disease or dysfunction as indicated by alanine transaminase (ALT) or aspartate transaminase (AST) greater than 2.5 times the upper limit of normal, bilirubin greater than 1.5 times the upper limit of normal, international normalized ratio (INR) greater than 1.5 in the absence of anticoagulation, or presence of diuretic refractory ascites.
* Elevation of ALT or AST up to 6 times the upper limit of normal is allowed if elevation is determined to be a consequence of immune dysregulation by the site Principal Investigator and if the elevation has been stable for 3 months prior to enrollment.
* History of significant renal injury/renal disease severely affecting renal function or presence of impaired renal function as indicated by estimated glomerular filtration rate of less than 30 mL/min/1.73 m2.
15. A positive hepatitis B surface antigen (HBsAg), positive hepatitis B PCR, positive hepatitis C PCR, or positive hepatitis C antibody result at screening.
16. Administration of live vaccines starting from 6 weeks before first dose of study medication
17. Subject has a history of malignancy (except lymphoma) within 3 years before the first dose of study medication or has evidence of residual disease from a previously diagnosed malignancy, except for adequately treated cancers of the skin (basal or squamous cell) or carcinoma in situ of the uterine cervix.
18. Subject has a previous diagnosis of lymphoma that has been treated with chemotherapy, radiotherapy, or transplant within 1 year of the first dose of study medication or is anticipated to require lymphoma treatment within 6 months of the first dose of study medication.
19. Subject has uncontrolled post-transplant lymphoproliferative disease-like Epstein-Barr virus related lymphoproliferative disease.
20. Donation or loss of 400mL or more of blood within 8 weeks before the first dose of study medication
21. Subject has had major surgery requiring hospitalization or radiotherapy within 4 weeks prior to the first dose of study medication or has a planned or expected major surgical procedure during the study period.
22. Pregnant or nursing (lactating) women.
23. Individuals of child-bearing potential, unless they are using highly effective methods of contraception
Minimum Eligible Age
12 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lahey Hospital & Medical Center
OTHER
Sponsor Role
collaborator
Pharming Technologies B.V.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Hospital Colorado
Aurora, Colorado, United States
Site Status
National Institute of Health
Bethesda, Maryland, United States
Site Status
Lahey Hospital & Medical Center
Burlington, Massachusetts, United States
Site Status
Mount Sinai Hospital
New York, New York, United States
Site Status
Texas Children's Hospital
Houston, Texas, United States
Site Status
IIS La Fe
Valencia, , Spain
Site Status
Leeds Teaching Hospital NHS Trust
Leeds, , United Kingdom
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Spain
United Kingdom
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LE 8201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study of LXR015-1 in HIV-Infected Patients
NCT00002365
COMPLETED
PHASE1
Evaluation of the Neurological and Psychiatric Adverse Events of Dolutegravir and Bictegravir in Real Life
NCT03964584
WITHDRAWN
Exploring Novel Mechanisms of Vaccine Failure LAIV Pilot Study
NCT02266992
COMPLETED
PHASE2
Safety And Efficacy Study Of CP-675,206 In HIV-Infected Patients
NCT00488995
WITHDRAWN
PHASE2
10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults
NCT05890963
ACTIVE_NOT_RECRUITING
PHASE1
Umbrella Study for HIV Infected Adults Enrolled in NIAID-Funded Interleukin-2 Studies
NCT00311688
COMPLETED
Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults
NCT03739866
COMPLETED
PHASE1
Immune Responses in HIV-Positive Patients Receiving an Anti-HIV Drug Combination When Given the HIV Vaccines Remune and vCP1452
NCT00006495
COMPLETED
PHASE1
Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults
NCT02960581
COMPLETED
PHASE1
Cabenuva Injection Tracking in CHORUS
NCT04863261
COMPLETED
NA
Immunogenicity of COVID-19 Vaccination in PLWH
NCT04894448
UNKNOWN
Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects
NCT01428596
UNKNOWN
PHASE1
A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus
NCT00000683
COMPLETED
PHASE1
Controlling Acute or Early HIV Infection With Antiretroviral Drugs, Without a Candidate Vaccine.As Reported Previously, the Candidate Vaccie Was Not Provided by the Maufacturer as Promised
NCT00238459
COMPLETED
A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons
NCT00001060
COMPLETED
PHASE1
Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption
NCT04340596
ACTIVE_NOT_RECRUITING
PHASE1
Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART
NCT00270205
COMPLETED
PHASE1/PHASE2
A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.
NCT00000846
COMPLETED
PHASE1
A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers
NCT00000868
COMPLETED
PHASE1
Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus
NCT03618056
COMPLETED
PHASE1
Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)
NCT00001041
COMPLETED
PHASE1
A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects
NCT00000795
COMPLETED
PHASE1
A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3
NCT00000857
COMPLETED
PHASE1
Effect of Leflunomide on T Cell Proliferation in HIV-Infected Patients
NCT00101374
COMPLETED
PHASE1